Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Time-to-progression ratio as a potential study endpoint in early-phase oncology trials: pooled analysis of phase II trials from the Australian MoST program.

Future oncology (London, England)·2026
Same author

BRAF-targeted therapy in non-melanomatous BRAF-mutant tumours: a systematic review of broad but histology-modulated efficacy.

International journal of clinical oncology·2026
Same author

A scalable, multi-resolution consensus clustering approach for prioritizing robust signals from high-throughput screens.

Briefings in bioinformatics·2026
Same author

Identifying therapeutic targets in low-grade serous ovarian carcinomas with no specific molecular profile.

The Journal of pathology·2026
Same author

Nivolumab and ipilimumab combination treatment in patients with advanced intrahepatic cholangiocarcinoma and gallbladder cancer: Results from the phase II MoST-CIRCUIT trial.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Impact of Spiritual Wellbeing in Advanced Cancer Patients Receiving Genomic Test Results.

Psycho-oncology·2026

Related Experiment Video

Updated: Jun 5, 2026

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis
12:03

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis

Published on: December 9, 2016

Targeting the p53 Pathway in Ewing Sarcoma.

Paul M Neilsen1, Kathleen I Pishas, David F Callen

  • 1Sarcoma Research Group, Discipline of Medicine, University of Adelaide and Hanson Institute, Frome Road, Adelaide, SA 5000, Australia.

Sarcoma
|January 4, 2011
PubMed
Summary
This summary is machine-generated.

p53 tumor suppressor is functional in most Ewing Sarcomas, unlike other cancers. Targeting this wild-type p53 with small molecules shows therapeutic promise for Ewing Sarcoma treatment.

More Related Videos

Yeast As a Chassis for Developing Functional Assays to Study Human P53
14:57

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Published on: August 4, 2019

Targeted and Selective Treatment of Pluripotent Stem Cell-derived Teratomas Using External Beam Radiation in a Small-animal Model
05:08

Targeted and Selective Treatment of Pluripotent Stem Cell-derived Teratomas Using External Beam Radiation in a Small-animal Model

Published on: February 17, 2019

Related Experiment Videos

Last Updated: Jun 5, 2026

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis
12:03

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis

Published on: December 9, 2016

Yeast As a Chassis for Developing Functional Assays to Study Human P53
14:57

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Published on: August 4, 2019

Targeted and Selective Treatment of Pluripotent Stem Cell-derived Teratomas Using External Beam Radiation in a Small-animal Model
05:08

Targeted and Selective Treatment of Pluripotent Stem Cell-derived Teratomas Using External Beam Radiation in a Small-animal Model

Published on: February 17, 2019

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Genetics

Background:

  • The p53 tumor suppressor is crucial for preventing cancer by halting oncogenic transformation.
  • TP53 gene mutations are common in many cancers, leading to dysfunctional p53.
  • Ewing Sarcomas uniquely retain functional wild-type p53 in most cases, with intact downstream pathways.

Purpose of the Study:

  • To review the role and regulation of p53 in Ewing Sarcoma.
  • To explore the interaction between p53 and the EWS-FLI1 gene rearrangement in Ewing Sarcoma.
  • To discuss the therapeutic potential of p53 activators for Ewing Sarcoma.

Main Methods:

  • Literature review of p53 function and regulation in Ewing Sarcoma.
  • Analysis of the interplay between p53 and EWS-FLI1.
  • Summary of emerging therapeutic strategies targeting p53.

Main Results:

  • Most Ewing Sarcomas express functional wild-type p53, differing from other malignancies.
  • p53 signaling and DNA-damage checkpoints are intact in these sarcomas.
  • Cross-talk exists between p53 and the EWS-FLI1 fusion oncogene.

Conclusions:

  • Ewing Sarcoma's reliance on functional wild-type p53 presents a therapeutic vulnerability.
  • Small molecule p53 activators are a promising strategy for treating Ewing Sarcomas with wild-type p53.
  • Further research into p53 modulation could lead to novel cancer therapies.